Fibrosis
Tissue transglutaminase (TG2) plays a central role in fibrosis, by recruiting TGF-β, disturbing extracellular matrix protein homeostasis and supporting fibroblast proliferation.
Zedira scientists developed a new class of tissue transglutaminase inhibitors: reversible mode-of-inhibition, potent and selective. The novel compounds were optimized for in vivo oral bioavailability and favourable pharmacokinetic profiles. We refer to the respective press release.
Proprietary drug candidates are therefore available to target dysregulated active TG2 in fibrotic disorders, of the lung, kidney, and liver.
Zedira offers partnerships for clinical development of these drug candidates.
Moreover, Zedira is planning to expand its global leadership position in the transglutaminase field by investing into follow-up drug discovery projects.
Interested? Then please do not hesitate contacting us: contact@zedira.com
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
Press release: Zedira announces ISO 9001:2015 certification
Design of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering